Edition:
United Kingdom

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

18.60USD
23 May 2018
Change (% chg)

$-0.87 (-4.47%)
Prev Close
$19.47
Open
$19.47
Day's High
$19.55
Day's Low
$18.40
Volume
77,830
Avg. Vol
207,131
52-wk High
$48.74
52-wk Low
$15.74

Chart for

About

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in... (more)

Overall

Beta: 4.21
Market Cap(Mil.): $1,122.56
Shares Outstanding(Mil.): 28.90
Dividend: --
Yield (%): --

Financials

  FPRX.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -4.24 -- --
ROI: -29.38 1.57 14.38
ROE: -31.27 2.43 16.07

BRIEF-Five Prime Therapeutics Reports Q1 Loss Per Share $0.63

* FIVE PRIME THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

08 May 2018

BRIEF-Five Prime Therapeutics Appointed Linda Rubinstein As Interim CFO

* FIVE PRIME THERAPEUTICS INC - ON APRIL 13 APPOINTED LINDA RUBINSTEIN AS INTERIM CHIEF FINANCIAL OFFICER - SEC FILING

17 Apr 2018

BRIEF-Five Prime Therapeutics To Close Bladder Cancer Cohort Of Its Phase 1 FPA144-001 Trial

* TO CLOSE BLADDER CANCER COHORT OF PHASE 1 TRIAL EVALUATING BEMARITUZUMAB TREATING PATIENTS WHOSE TUMORS OVEREXPRESS FGFR2B PROTEIN

10 Apr 2018

BRIEF-Personal Genome Diagnostics enteres into a collaboration with Five Prime Therapeutics

* CO INTENDS TO SUBMIT ASSAY FOR REGULATORY APPROVAL, COMMERCIALIZE IN U.S., EUROPE, JAPAN, CHINA, OTHER COUNTRIES

03 Apr 2018

BRIEF-Five Prime Therapeutics Starts Patient Dosing In Phase 1 Trial In Antibody Study

* FIVE PRIME THERAPEUTICS INITIATES PATIENT DOSING IN PHASE 1 TRIAL OF NOVEL FIRST-IN-CLASS B7-H4 ANTIBODY FPA150 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

28 Mar 2018

BRIEF-Five Prime Therapeutics Announces Executive Change

* ‍BELSKY WILL CONTINUE IN HIS CURRENT ROLE UNTIL APRIL 6, 2018​ Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

13 Mar 2018

BRIEF-Five Prime Reports Q4 Loss Per Share $1.04

* FIVE PRIME ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

27 Feb 2018

BRIEF-Five Prime Therapeutics Announces $25 Mln Payment By Bristol-Myers Squibb

* FIVE PRIME THERAPEUTICS ANNOUNCES $25 MILLION PAYMENT BY BRISTOL-MYERS SQUIBB FOR CABIRALIZUMAB DEVELOPMENT MILESTONE

25 Jan 2018

BRIEF-Five Prime Announces Pricing Of Upsized Public Offering Of Common Stock

* FIVE PRIME ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF COMMON STOCK

25 Jan 2018

BRIEF-Five Prime Announces Proposed Public Offering Of Common Stock

* FIVE PRIME ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

23 Jan 2018

Competitors

Earnings vs. Estimates